

Supplement S1

Table S1. Patients' characteristics.

Characteristic	Category	Value
Subjects, n		24
Age (years), median [IQR], maximum, minimum		61 [50-65] 78, 29
Gender, n (%)	Female Male	17 (71%) 7 (29%)
Main diagnosis, n (%)	Mental and behavioral disorders (ICD-10: F) Diseases of the musculoskeletal system and connective tissue (ICD-10: M) Diseases of the circulatory system (ICD-10: I) Others ¹	9 (38%) 7 (29%) 5 (20%) 3 (13%)
Initial reason for PGx testing, n (%)	Reactive Preemptive	20 (83%) 4 (17%)
Suspected ATC-group for reactive testing, n (%)	B01A: Antithrombotic agents C07A: Beta blocking agents C10A: Lipid modifying agents M01A: Anti-inflammatory and antirheumatic products, non-steroids N02A: Opioids N06A: Antidepressants	4/20 (20%) 2/20 (10%) 1/20 (5%) 3/20 (15%) 8/20 (40%) 6/20 (30%)
Time since PGx testing (years), median [IQR] maximum, minimum		2 [1-3] 5, 1
Time spend for follow up in minutes, median [IQR] maximum, minimum		15 [10-20] 30, 10

¹Other diseases include diagnoses of ICD-10: E (endocrine, nutritional and metabolic diseases), and ICD-10: H (diseases of the eye and adnexa).

Abbreviation: ATC, anatomical therapeutic chemical; ICD-10, International Classification of Diseases 10th Revision; IQR, interquartile range; n, number.